Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 606398, 8 pages
http://dx.doi.org/10.1155/2013/606398
Research Article

Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy

Department of Breast Surgery, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, Liaoning 110004, China

Received 21 May 2013; Accepted 2 July 2013

Academic Editors: S. Holdenrieder, H.-W. Lo, and Y. Yu

Copyright © 2013 Jianyi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann, and H.-J. Senn, “Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011,” Annals of Oncology, vol. 22, no. 8, pp. 1736–1747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Mersin, K. Gülben, U. Berberoǧlu et al., “Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?” World Journal of Surgery, vol. 35, no. 10, pp. 2196–2202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry,” Cancer, vol. 109, no. 9, pp. 1721–1728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Chen, Z. Jiang, Z. Shao, Q. Sun, and K. Shen, “An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer,” Value in Health, vol. 12, no. 3, pp. S82–S84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred, “Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1474–1481, 1999. View at Google Scholar · View at Scopus
  6. M. C. U. Cheang, S. K. Chia, D. Voduc et al., “Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer,” Journal of the National Cancer Institute, vol. 101, no. 10, pp. 736–750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Desantis, R. Siegel, P. Bandi, and A. Jemal, “Breast cancer statistics, 2011,” CA Cancer Journal for Clinicians, vol. 61, no. 6, pp. 409–418, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. La Vecchia, C. Bosetti, F. Lucchini et al., “Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975,” Annals of Oncology, vol. 21, no. 6, pp. 1323–1360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. C. Geyer, D. N. Rodrigues, B. Weigelt, and J. S. Reis-Filho, “Molecular classification of estrogen receptor-positive/luminal breast cancers,” Advances in Anatomic Pathology, vol. 19, no. 1, pp. 39–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Rastelli, S. Biancanelli, A. Falzetta et al., “Triple-negative breast cancer: current state of the art,” Tumori, vol. 96, no. 6, pp. 875–888, 2010. View at Google Scholar · View at Scopus
  11. Y. Akasbi, S. Bennis, F. Abbass et al., “Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez),” BMC Research Notes, vol. 4, article 500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. J. Howell, A. M. Wardley, and A. C. Armstrong, “Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer,” Journal of the National Cancer Institute, vol. 101, no. 24, pp. 1730–1731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Tancini and A. Rossi, “Surgery and chemotherapy in early breast cancer,” Schweizerische Medizinische Wochenschrift, vol. 107, no. 28, pp. 1005–1007, 1977. View at Google Scholar · View at Scopus
  14. H. Jinno, T. Ikeda, K. Kubouchi, K. Fujiwara, and M. Kitajima, “Adjuvant chemotherapy for breast cancer–a current controversy,” Gan To Kagaku Ryoho, vol. 31, no. 2, pp. 176–180, 2004. View at Google Scholar · View at Scopus
  15. J. Chilcott, M. Lloyd Jones, and A. Wilkinson, “Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal,” Health Technology Assessment, vol. 13, supplement 1, pp. 7–13, 2009. View at Google Scholar · View at Scopus